Despite intensive global effort for more than a decade, we are still unable to unite our view of whether TCF7L2 variants in T2D risk subjects represent gain-of-function or loss-of-function events [1,14–16]. The gene discussed is TCF7L2; the disease is type 2 diabetes mellitus.